STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib

[1]  Pengyuan Liu,et al.  Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer , 2014, Proceedings of the National Academy of Sciences.

[2]  S. Masuda,et al.  Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Jian Zhu,et al.  A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib , 2017, Mayo Clinic proceedings. Innovations, quality & outcomes.

[4]  H. Moch,et al.  STRN-ALK Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment , 2019, JCO precision oncology.

[5]  L. Zeng,et al.  Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.